Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019030629) A COMPOSITION FOR ORAL ADMINISTRATION IN THE THERAPEUTIC OR PREVENTIVE TREATMENT OF GASTROESOPHAGEAL REFLUX DISORDERS OR DISEASE
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

CLAIMS

1. A composition comprising

- an effective amount of a mixture comprising or, alternatively, consisting of:

(a) an extract of Trigonella foenum graecum and

(b) a block copolymer of ethylene oxide and propylene oxide with the following structural formula:

HO-(CH2-CH2-0)x-(CH2-CH(CH3)-0)y-(CH2-CH2-0)x-H

wherein x and y are, independently of each other, a number comprised between 20 and 200, and - at least one excipient or inert ingredient suitable for pharmaceutical or alimentary use.

2. The composition according to claim 1 , wherein said extract of Trigonella foenum graecum (a) is present in an amount comprised from 10% to 95% by weight relative to the total weight of the composition, preferably in a concentration by weight comprised from 25% to 85% relative to the total weight of the composition.

3. The composition according to any one of the preceding claims, wherein the block copolymer (b) is a poloxamer.

4. The composition according to claim 3, wherein poloxamer is present in an amount comprised from 1% to 80% by weight relative to the total weight of the composition, preferably wherein poloxamer is present in a concentration by weight comprised from 2.5% to 60% relative to the total weight of the composition.

5. The composition for use according to claim 3 or 4, wherein the block copolymer (b) is poloxamer 188 (wherein approximately x=80 and y=27), with a molecular weight comprised between 7680 Da and 9510 Da, or poloxamer 407 (approximately x=101 , y=56), with a molecular weight comprised between 9840 Da and 14600 Da, or a mixture thereof.

6. The composition according to claim 5, wherein the block copolymer (b) is a mixture of poloxamer 407 and poloxamer 188, preferably with a ratio by weight comprised between 4: 1 and 0.5: 1, more preferably comprised between 2:1 and 1 :1.

7. The composition according to any one of the preceding claims, wherein said composition is for use in a method of therapeutic or preventive treatment of gastroesophageal reflux disorders or disease and its associated disorders and pathologies in a subject in need thereof.

8. The composition for use according to claim 7, wherein said composition is in a form suited to oral administration to said subject.

9. Non-therapeutic use of a composition according to any one of claims 1 to 6 for the non-therapeutic treatment of a gastroesophageal reflux disorder or a disorder associated with gastroesophageal reflux in a patient in need of such non-therapeutic treatment.